The Pharma Letter Last September, Stivarga was approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan -based chemotherapy, an anti-VEGF therapy, and, if KRAS ... and more »
PR Newswire (press release) ... malate.1 Last September, Stivarga was approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan -based chemotherapy, an anti-VEGF therapy, and ... and more »
Wall Street Journal (press release) ... Session) Title: DOC-MEK: A double-blind randomized Phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma (Abstract # 9068) Presenter: Avinash Gupta, MBBS BSc MRCP Date: Saturday, June 1, ... and more »
MarketWatch Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on ... and more »
PharmiWeb.com (press release) Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on ... and more »
Seeking Alpha In August 2012, the FDA approved Zaltrap (ziv-aflibercept), developed in partnership with Sanofi (NYSE: SNY) in combination with 5-fluorouracil, leucovorin and irinotecan for treatment of metastatic colorectal cancer in adults. The European Medicines ...
pharmabiz.com In addition, Pexa-Vec is being evaluated in a phase I-II clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a phase IIa clinical trial in treatment-refractory kidney cancer ...
